Cancer Vaccines

Annual Report Announcement 2006

Published in Cancer Weekly, March 20th, 2007

The board of directors in Pharmexa A/S has today approved the audited financial report for the financial year 2006. The report shows a loss of DKK 169.1 million which is in accordance with the company's latest published expectations.

Position at the balance sheet date, summary:

2006 was a year of progress where the focus was on the integration and further development of the two new project portfolios from GemVax and Pharmexa-Epimmune. The most important result was the approval and initiation of a phase III study with the cancer vaccine GV1001 which has the potential to change the way cancer is treated in the future. Phase III studies are the final...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2007-03-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry